Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Ireland: Hepatitis C drug to be made available

Minister for Health Leo Varadkar is to make available potentially life-saving treatments for hepatitis C – provided agreement on price can be reached with the manufacturers.

Published
13 hours ago
From
The Irish Times
Advocates Criticize Plans to Restrict N.Y. Hepatitis C Drugs

Advocates argue that the proposed criteria are dangerous for people living with the deadly liver disease.

Published
13 hours ago
From
Poz magazine news
Unique 'pay if you clear' proposal for new hepatitis drug

The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

Published
15 October 2014
From
BBC
As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

Published
10 October 2014
From
Forbes
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Harvoni’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.

Published
10 October 2014
From
Gilead press release
Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Thousands of Hepatitis C virus patients have flooded two medical centers in Alexandria in hopes of receiving the new Hep C Sovaldi drug, after the health ministry said it will be providing it for patients.

Published
10 October 2014
From
Egypt Independent
Sovaldi ‘unaffordable’ says NHS documents

Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

Published
08 October 2014
From
Pharmafile
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill

Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus.

Published
07 October 2014
From
Forbes
Most Spanish patients coinfected with HIV/HCV called difficult to cure

Most patients coinfected with HIV and hepatitis C virus infection at a clinic in Spain were considered “difficult to cure” primarily because of their HCV genotype and other factors, according to data presented at the AASLD/EASL Special Conference on Hepatitis C.

Published
07 October 2014
From
Healio
New Hepatitis C Treatment Too Pricey For All Patients

There's a brand-new drug to treat Hepatitis C, but only a small percentage of patients enrolled in the state's Medicaid program are receiving it. The drug Sovaldi is supposed to work quicker and with fewer side effects than other medications that treat HCV. Arizona's Medicaid program limits coverage for effective but expensive drug.

Published
07 October 2014
From
KJZZ Radio
← First12345...45Next →

Filter by country